leisure time -WSS

leisure time

author：knowledge 2025-09-27 09:47:18 - browse：7

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： What Mike Pence has said that could be used in a Donald Trump trial

Wikipedia

WSS

My superpower is killing ticks

What the cancer research community can learn from the Covid response

Roche acquires Telavant from Roivant, adding experimental IBD treatment

ER docs worry over extreme heat as a 'mass casualty event'

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Stem cell clinics for heart failure: buyer be wary

entertainment

leisure time

hotspot

Medical leaders decry Supreme Court decision on affirmative action

STAT Summit: The economic case for universal basic health care

New air purifier tech could be key to improving indoor air quality

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

State Dept. review finds Biden bears some blame for Afghanistan failures

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

ChatGPT in medicine: STAT answers readers' burning questions

STAT Summit: The economic case for universal basic health care

Medicare proposal to cover medical devices draws a mixed reaction

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

explore

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

UnitedHealth, Optum discontinue NaviHealth name

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Gilgo Beach: Police identify another victim in serial killing investigation

Attacks on the drug industry will lead to fewer breakthroughs

For BCIs, commercial hurdles may be bigger than scientific ones

leisure time

Wikipedia

Wikipedia

hotspot